VANTAS delivers more freedom
and flexibility in 4 key ways:

Chart your patients’ course for more freedom with proven
clinical efficacy

VANTAS provides a full year of efficacy through the continuous release of histrelin

100% of evaluable patients at week 4 (n=134) attained chemical castration (testosterone levels <50 ng/dL)

When a 17 patient cohort from the above study was evaluated for intensive pharmacokinetic analysis, mean testosterone levels decreased by week 2.

Following an initial rise, mean serum testosterone levels began to decrease by day 2 (n=17)

Mean serum testosterone levels decreased below baseline by week 2 (n=17)

And rapid and continuous PSA suppression

VANTAS resulted in decreased PSA levels in 100% of study patients

By week 4, 100% of patients (n=138) experienced a significant decrease in PSA levels¹

By week 24, 93% of patients that successfully completed 52 weeks of treatment (n=111) experienced a decrease in serum PSA to within normal limits

Reference: 1. Data on file, Indevus Pharmaceuticals, Inc., 2003.

Important Safety Information

VANTAS is contraindicated in women, pediatric patients and patients with hypersensitivity to GnRH, GnRH agonist analogs, or any of the other components of VANTAS.

VANTAS, like other LHRH agonists, causes a transient increase in serum concentrations of testosterone during the first week of treatment. Patients may experience worsening of symptoms or onset of new symptoms, including bone pain, neuropathy, hematuria, or ureteral or bladder outlet obstruction, cases of ureteral obstruction and spinal cord compression. Patients with metastatic vertebral lesions and/or with urinary tract obstruction should be closely observed during the first few weeks of therapy.

Implant insertion and removal is a surgical procedure and should use aseptic technique. Careful adherence to the recommended insertion and removal procedures is recommended. In all clinical trials combined, an implant was not recovered in 8 patients, 2 of these 8 patients had serum testosterone levels above castrate level and the implant was not visualized with ultrasound. In all of the 8 patients, the implant was not palpable.

Response to VANTAS should be monitored measuring serum concentrations of testosterone and PSA periodically.

In clinical trials, the most common adverse reactions were hot flashes, fatigue, and implant site reaction. During post-marketing surveillance, rare cases of pituitary apoplexy have been reported after the administration of GnRH agonists.

VANTAS delivers more freedom and flexibility in 4 key ways:

Click here for a larger view

Important Safety Information

VANTAS delivers more freedom
and flexibility in 4 key ways: